
vTv Therapeutics Inc
NASDAQ:VTVT

Intrinsic Value
The intrinsic value of one
VTVT
stock under the Base Case scenario is
7.01
USD.
Compared to the current market price of 19.45 USD,
vTv Therapeutics Inc
is
Overvalued by 64%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
vTv Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
vTv Therapeutics Inc
Balance Sheet Decomposition
vTv Therapeutics Inc
Current Assets | 38.1m |
Cash & Short-Term Investments | 36.7m |
Receivables | 62k |
Other Current Assets | 1.3m |
Non-Current Assets | 153k |
PP&E | 153k |
Free Cash Flow Analysis
vTv Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
vTv Therapeutics Inc
Revenue
|
1m
USD
|
Operating Expenses
|
-25.2m
USD
|
Operating Income
|
-24.2m
USD
|
Other Expenses
|
5.7m
USD
|
Net Income
|
-18.5m
USD
|
VTVT Profitability Score
Profitability Due Diligence
vTv Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Score
vTv Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
VTVT Solvency Score
Solvency Due Diligence
vTv Therapeutics Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Score
vTv Therapeutics Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VTVT Price Targets Summary
vTv Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
VTVT
is 36.21 USD
with a low forecast of 35.35 USD and a high forecast of 37.8 USD.
Dividends
Current shareholder yield for VTVT is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
VTVT
stock under the Base Case scenario is
7.01
USD.
Compared to the current market price of 19.45 USD,
vTv Therapeutics Inc
is
Overvalued by 64%.